MedPath

Assessment of liver function with Dynamic Contrast-Enhanced MRI in patients scheduled for liver resection - a pilot study.

Completed
Conditions
Liver cancer
liver metastasis
10019815
Registration Number
NL-OMON46928
Lead Sponsor
Academisch Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

* Patients diagnosed with one or more liver lesions who are scheduled for 99mTc-HBS
* Visit 1 scheduled within preferably 7 but at most 14 days before or after 99mTc-HBS (with at least 4 hours between visits if scheduled on the same day)
* Age *18 years
* Signed informed consent obtained prior to any study-specific procedure

Exclusion Criteria

* General contraindications for MRI (such as pregnancy and claustrophobia)
* Chronic renal insufficiency or eGFR < 30 ml/min/1.73 m2
* Known or family history of congenital prolonged QT-syndrome
* Prior history of arrhythmia after the use of cardiac repolarisation time prolonging drugs
* Prior history of allergic reaction to gadolinium-containing compounds
* Prior history of asthma bronchiale
* Prior history allergic conditions

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>* DCE-MRI: maximum enhancement, time to peak, slope of enhancement, wash-out<br /><br>rate<br /><br>* Quantitative T1 mapping: *T1<br /><br>* 99mTc-HBS (performed as part of clinical work-up): liver uptake function</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>* Liver fat percentages (MR fat mapping)<br /><br>* Liver microperfusion (IVIM)<br /><br>* Histology results of the microscopic examination of the resected liver:<br /><br>* Degree of fibrosis and steatosis<br /><br>* Histology results of the microscopic examination of the liver biopsy of the<br /><br>future remnant liver:<br /><br>* Degree of fibrosis and steatosis</p><br>
© Copyright 2025. All Rights Reserved by MedPath